Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. Show more

Location: 1185 Avenue of the Americas, New York, NY, 10036, United States | Website: https://www.oramed.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

86.6M

52 Wk Range

$1.82 - $3.09

Previous Close

$2.12

Open

$2.12

Volume

17,725

Day Range

$2.09 - $2.15

Enterprise Value

-39.35M

Cash

130.6M

Avg Qtr Burn

-2.614M

Insider Ownership

13.58%

Institutional Own.

19.11%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORMD-0801 (ORA-D-013-1) Details Diabetes, Type 2 diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORMD-0801 Details Non-alcoholic steatohepatitis , Liver disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.